Aurinia Pharmaceuticals announced that the Swiss Agency for Therapeutic Products, or "Swissmedic," has granted marketing authorization of Lupkynis in combination with a background immunosuppressive therapy to treat adults with active class III, IV and V, including mixed classes III/V and IV/V, lupus nephritis, or LN. "In addition, we have received Orphan Drug designation in Switzerland, granting 15 years of drug exclusivity protection in association with approval," the company stated.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AUPH:
- Aurinia Pharmaceuticals price target raised to $13 from $11 at RBC Capital
- AUPH Earnings this Week: How Will it Perform?
- Aurinia Pharmaceuticals call volume above normal and directionally bullish
- Biotech Alert: Searches spiking for these stocks today
- Cantor says Aurinia M&A takeout chatter ‘picks back up’ after MKT letter